We are thrilled to announce a groundbreaking scientific study authored by Mathieu Frechin and Daniel Olive, in collaboration with Aix Marseille Université, ImCheck therapeutics, and Nanolive. Their remarkable research on Vγ9Vδ2 T cells has opened up new possibilities for potent cancer immunotherapies.
In this study, they investigated the role of BTN2A1, a surface protein that binds to the Vγ9 chain of the γδ TCR, in modulating Vγ9Vδ2 T cell functions. The team discovered a monoclonal anti-BTN2A1 agonist antibody called 107G3B5, which demonstrated remarkable potential in enhancing Vγ9Vδ2 T cell responses.
Through the use of cutting-edge computer vision strategies applied to holotomographic microscopy videos, the researchers observed that 107G3B5 significantly improved the interaction between Vγ9Vδ2 T cells and target cells.
This enhancement occurred both quantitatively and qualitatively, paving the way for more effective immunotherapies against hematological and solid cell lines. Furthermore, this antibody also exhibited positive effects on primary cells from adult acute lymphoblastic leukemia patients.
The study also shed light on the mechanisms behind this improved response. The activated Vγ9Vδ2 T cells, triggered by 107G3B5, induced caspase 3/7 activation in tumor cells, leading to their death through pyroptosis. This remarkable discovery highlights the potential of targeting BTN2A1 with 107G3B5, not only in enhancing the Vγ9Vδ2 T cell antitumor response but also in promoting immunogenic cell death.
We applaud the collaborative efforts of Mathieu Fréchin, Daniel Olive, Christophe Dubois, Aix-Marseille University, ImCheck Therapeutics, and Nanolive SA, which have yielded groundbreaking insights into cancer immunotherapy. This research has the potential to revolutionize the field and bring us closer to powerful new treatment options for cancer patients.
Stay tuned for more updates as we continue to explore the incredible possibilities that arise from this extraordinary research collaboration!
Read the full article here
Read our latest news
Closer to understanding coronavirus: Research results with Institut Pasteur
Nanolive is proud to be part of a research collaboration with leading virologists from the group of Olivier Schwartz at the Institut Pasteur in Paris. The latest research from Nanolive’s Deep Quantitative Biology department and the Institut Pasteur uses cutting-edge...
Nanolive is exhibiting at the ASCB I EMBO Meeting, Cell Bio 2023. December 3 – 5 in Boston
Presentation Nanolive is delighted to invite you to attend our upcoming presentation at the Cell Bio Meeting in Boston on December 4, 2023, from 10:15am to 11:00am in Theatre 1. During our talk, “High-content label-free imaging for live phenotypic insights and...
Nanolive is exhibiting during the ESMO Congress 2023 October 20 – 23 in Madrid, Spain
💫Visit our booth:The world’s leading cancer research minds will converge at the ESMO Congress 2023. We are thrilled to announce that Nanolive will be exhibiting there from October 20 to 23, at Booth #560 in Hall 5! Come and meet our team and discover the...
